As of January 22, 2025, Lyell Immunopharma (LYEL) has a market cap of $0.17 billion USD. According to our data, Lyell Immunopharma is ranked No.7266 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.17 B |
-10.08%
|
Dec 31, 2024 | $0.19 B |
-67.01%
|
Dec 29, 2023 | $0.57 B |
-44.09%
|
Dec 30, 2022 | $1.01 B |
-55.17%
|
Dec 31, 2021 | $2.26 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Sana Biotechnology
SANA
|
$0.78 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Market Cap | = | LYEL Stock Price | * | LYEL Shares Outstanding |
= | $0.58 | * | 0.29 B | |
= | $0.17 B |